Tiziana Life Sciences Ltd
TLSA
$0.81
$0.00991.24%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.40M | 9.13M | 9.87M | 9.93M | 9.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.80M | 16.89M | 17.98M | 18.37M | 18.77M |
| Operating Income | -15.80M | -16.89M | -17.98M | -18.37M | -18.77M |
| Income Before Tax | -16.61M | -16.92M | -17.24M | -18.37M | -19.50M |
| Income Tax Expenses | -2.88M | -1.21M | 449.00K | 224.50K | -- |
| Earnings from Continuing Operations | -13.73 | -15.71 | -17.69 | -18.60 | -19.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.73M | -15.71M | -17.69M | -18.60M | -19.50M |
| EBIT | -15.80M | -16.89M | -17.98M | -18.37M | -18.77M |
| EBITDA | -15.79M | -16.88M | -17.98M | -18.37M | -18.76M |
| EPS Basic | -0.13 | -0.15 | -0.17 | -0.18 | -0.19 |
| Normalized Basic EPS | -0.09 | -0.10 | -0.10 | -0.11 | -0.11 |
| EPS Diluted | -0.13 | -0.15 | -0.17 | -0.18 | -0.19 |
| Normalized Diluted EPS | -0.09 | -0.10 | -0.10 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 411.54M | 410.71M | 409.88M | 412.34M | 414.79M |
| Average Diluted Shares Outstanding | 411.54M | 410.71M | 409.88M | 412.34M | 414.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |